Artiva Biotherapeutics, Inc. Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount
Artiva Biotherapeutics, Inc. (ARTV) reported Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount of 4.81 million shares for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Income Statement › Earnings Per Share
us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount · last filed 2026-08-06
- Artiva Biotherapeutics, Inc. antidilutive securities excluded from computation of earnings per share, amount for the quarter ending 2026-03-31 was 4.96M shares, a 32.77% increase year-over-year.
- Artiva Biotherapeutics, Inc. antidilutive securities excluded from computation of earnings per share, amount for the quarter ending 2025-03-31 was 3.73M shares, a 51.40% decline year-over-year.
- Artiva Biotherapeutics, Inc. antidilutive securities excluded from computation of earnings per share, amount for the quarter ending 2024-03-31 was 7.68M shares.
- Artiva Biotherapeutics, Inc. antidilutive securities excluded from computation of earnings per share, amount for fiscal 2025 was 3.58M shares, a 30.54% increase from fiscal 2024.
- Artiva Biotherapeutics, Inc. antidilutive securities excluded from computation of earnings per share, amount for fiscal 2024 was 2.75M shares, a 63.39% decline from fiscal 2023.
- Artiva Biotherapeutics, Inc. antidilutive securities excluded from computation of earnings per share, amount for fiscal 2023 was 7.50M shares.
| Period end | Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount 3 month | Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount 6 month | Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount 9 month | Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount 12 month |
|---|---|---|---|---|
| 2026-06-30 | 4.81M shares 10-Q · filed 2026-08-06 | |||
| 2026-03-31 | 4.96M shares 10-Q · filed 2026-05-08 | |||
| 2025-12-31 | 3.58M shares 10-K · filed 2026-03-10 | |||
| 2025-09-30 | 3.66M shares 10-Q · filed 2025-11-12 | |||
| 2025-06-30 | 3.80M shares 10-Q · filed 2026-08-06 | |||
| 2025-03-31 | 3.73M shares 10-Q · filed 2026-05-08 | |||
| 2024-12-31 | 2.75M shares 10-K · filed 2026-03-10 | |||
| 2024-09-30 | 2.77M shares 10-Q · filed 2025-11-12 | |||
| 2024-06-30 | 7.99M shares 10-Q · filed 2025-08-06 | |||
| 2024-03-31 | 7.68M shares 10-Q · filed 2025-05-08 | |||
| 2023-12-31 | 7.50M shares 10-K · filed 2025-03-24 | |||
| 2023-09-30 | 7.51M shares 10-Q · filed 2024-11-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Cabaletta Bio, Inc. (CABA) | United States | $0.365B | -2.81 |
| FENNEC PHARMACEUTICALS INC. (FENC) | United States | $0.371B | -115.85 |
| C4 Therapeutics, Inc. (CCCC) | United States | $0.373B | -5.65 |
| AGENUS INC (AGEN) | United States | $0.383B | 1.41 |
| Ocugen, Inc. (OCGN) | United States | $0.343B | -6.34 |
| Surrozen, Inc./DE (SRZN) | United States | $0.395B | |
| Zura Bio Ltd (ZURA) | $0.398B | -6.56 | |
| Scribe Therapeutics, Inc. (SCTX) | United States | $0.410B | |
| Editas Medicine, Inc. (EDIT) | United States | $0.424B | -4.29 |
| Century Therapeutics, Inc. (IPSC) | United States | $0.306B | -4.02 |